SCHEMBL4871001

SCHEMBL4871001

NC(=O)c1ccccc1C1(C(=O)O)CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.55
HDAC4 P56524 5/20 0.44
NPC1 O15118 2/20 0.44
BCAT2 O15382 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 1/20 0.40
METAP2 P50579 1/20 0.39
CTNNB1 P35222 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
GAA P10253 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23920040 0.86 AKR1C1 (0.58) AKR1C1HDAC4NPC1MEN1KMT2A
SCHEMBL27152666 0.86 AKR1C1 (0.58) AKR1C1HDAC4MEN1KMT2ASMN1; SMN2
SCHEMBL23920039 0.84 AKR1C1 (0.60) AKR1C1HDAC4MEN1KMT2AKDM4E
Silver SCHEMBL7493163 0.83 NPC1 (0.41) AKR1C1HDAC4NPC1BCAT2MEN1
SCHEMBL28008915 0.81 AKR1C1 (0.53) AKR1C1HDAC4MEN1KMT2AALDH1A1
SCHEMBL7226244 0.81 PARP1 (0.50) NPC1PARP1
SCHEMBL31189199 0.80 AKR1C1 (0.55) AKR1C1HDAC4MEN1KMT2AKDM4E
SCHEMBL22745669 0.80 AKR1C1 (0.55) AKR1C1HDAC4MEN1KMT2AKDM4E
SCHEMBL10590809 0.79 NPC1 (0.44) NPC1KDM4EALDH1A1MAPTHPGD
SCHEMBL3918459 0.78 AKR1C1 (0.62) AKR1C1HDAC4MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0640605-B1 SPIROPYRAN COMPOUND, OPTICALLY ACTIVE SPIROPYRAN COMPOUND, AND USE THEREOF OTSUKA KAGAKU KK (JP) 2002-06-12 EP claimed
US-5521269-A Spiropyran compounds and optically active spiropyran compounds and their use OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1996-05-28 US claimed
EP-0640605-A1 SPIROPYRAN COMPOUND, OPTICALLY ACTIVE SPIROPYRAN COMPOUND, AND USE THEREOF OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1995-03-01 EP claimed
JP-1113350-A None JP disclosed
JP-2032046-A None JP disclosed
JP-2067237-A None JP disclosed
US-20140142337-A1 1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID AMIDE AND SALT THEREOF, AND METHOD FOR PRODUCING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2014-05-22 US disclosed
EP-2725012-A1 1-AMINO-2-VINYL CYCLOPROPANE CARBOXYLIC ACID AMIDE, SALT OF SAME, AND METHOD FOR PRODUCING SAME Mitsubishi Gas Chemical Company, Inc. (JP) 2014-04-30 EP disclosed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
EP-1236722-B1 Optically active 4-(tert-butoxycarbonyl) piperazine compound, and method for producing the same SUMITOMO CHEMICAL CO (JP) 2006-04-19 EP disclosed
EP-1227085-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE DERIVATIVE AND OPTICAL RESOLVER THEREFOR TAKEDA PHARMACEUTICAL (JP) 2006-03-15 EP disclosed
EP-0858992-A1 PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-08-19 EP disclosed
EP-0776883-A1 Adduct salts of substituted benzylamine and a process for optically resolving them Ajinomoto Co., Inc. (JP) 1997-06-04 EP disclosed
US-5593967-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1997-01-14 US disclosed
US-5521269-A Spiropyran compounds and optically active spiropyran compounds and their use OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1996-05-28 US disclosed
EP-0640605-A1 SPIROPYRAN COMPOUND, OPTICALLY ACTIVE SPIROPYRAN COMPOUND, AND USE THEREOF OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1995-03-01 EP disclosed
US-5273983-A 2-Piperidinylmethylcyclohexylaminocarbonyl-substituted benzene LABORATORIES JACQUES LOGEAIS (FR) 1993-12-28 US disclosed
JP-H0267237-A PRODUCTION OF OPTICALLY ACTIVE 1,1,1-TRIFLUORO-2-ALKANOL YAMAKAWA YAKUHIN KOGYO KK 1990-03-07 JP disclosed
JP-H0232046-A PRODUCTION OF OPTICALLY ACTIVE 1-METHYL-3-PHENYL-PROPYLAMINE TORAY IND INC 1990-02-01 JP disclosed
JP-H01113350-A OPTICAL RESOLUTION OF (+) AND (-)-1-(4-BROMOPHENYL) ETHYLAMINE TORAY IND INC 1989-05-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142337-A1 1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID AMIDE AND SALT THEREOF, AND METHOD FOR PRODUCING SAME ALDH7A1, ALAD, BCAT1 AKR1C1 353/4885HDAC4 3824/4885NPC1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.